Wednesday, October 4, 2023
Wednesday, October 4, 2023

Contact: 561.316.3330

Trajan Group Acquires Axel Semrau GmbH

Global analytical science and device company Trajan Group Holdings Limited (ASX: TRJ) (Trajan or the Company) has completed the acquisition of Axel Semrau GmbH & Co. KG and Semrau Immobilien GmbH & Co. KG, the private business and properties of “Axel Semrau” based in Sprockhövel, Germany for €14.75 million and €2.25 million respectively. Adjustments, including accumulated undistributed profits total €2.85 million in favour of the sellers, to be paid by Trajan following Closing. Trajan is funding its current acquisition activities through a combination of cash and debt.

Axel Semrau employs just over 50 staff in Europe and develops and manufactures laboratory automation and chromatography software and detection systems. The company reported FY 21 (year ended Sept ’21) revenues of €14.9 million, and EBITDA of €1.46 million (normalized EBITDA of €1.67 million), unaudited.

Stephen Tomisich, Chief Executive Officer and Managing Director, Trajan stated, “We welcome the Axel Semrau team to the Trajan group. Trajan’s automation business and Axel Semrau have worked in close cooperation for several years and so we enter this new stage with a working relationship already well established. Axel Semrau owns and develops the CHRONOS intelligent sequencing software platform upon which Trajan’s automated workflows are built. We intend to further invest in CHRONOS in line with Trajan’s goal to simplify and automate complex analytical workflows.”

“Further, Axel Semrau’s automation business is highly synergistic with our own; both in terms of application areas and geographical coverage. Axel Semrau’s presence in chromatography and portable/on line gas detection also align with Trajan’s general direction.”

The two Managing Directors at Axel Semrau, Frank Sasse and Andreas Bruchmann and all other employees will continue in their current roles as part of the Trajan group. Dr Bruchmann commented “We welcome the opportunity to become part of the Trajan team. We have known Trajan for some time and find that our goals and values are aligned. We also see the intention of ongoing investment to drive growth in our business and capabilities.”

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Akura Medical, a Shifamed Portfolio Company, Closes $35M in Series B Financing

Akura Medical reports the funds will be used to apply for FDA 510(k) clearance for the Akura Mechanical Thrombectomy Platform, support clinical trials for additional indications, and scale manufacturing capabilities.

Laverock Therapeutics Raises £13.5M

Laverock Therapeutics notes the funding will enable further development of the GEiGS technology and progression of Laverock’s programs in regenerative medicine and immuno-oncology, with a focus on Type I Diabetes and solid tumor responsive T-cell and macrophage-based immune therapies, through to in vitro and in vivo validation.

SpineX Receives NIH SBIR Phase II Award for SCiP Clinical Trial in Children With CP

These funds will go towards completing a pivotal clinical trial to test the efficacy and safety of our proprietary SCiP™ device in children living with Cerebral Palsy (CP) notes SpineX.

Summus Raises $19.5 Million

Fundraise supports market expansion with Summus emerging as the premier clinical platform to share and access high quality specialty expertise across the continuum of care — serving employers, payers, health systems and physician groups.

Thirona Raises €7,5 Million New Financing to Accelerate the Adoption of its Breakthrough Innovations for Precision Medicine

With this financing, Thirona plans to accelerate the adoption of its break-through innovations for precision medicine.

By using this website you agree to accept Medical Device News Magazine Privacy Policy